John R. Wunderlich spends much of his time researching Immunology, Melanoma, Adoptive cell transfer, Antigen and Immunotherapy. John R. Wunderlich regularly links together related areas like Cancer research in his Immunology studies. He focuses mostly in the field of Melanoma, narrowing it down to matters related to Cancer and, in some cases, Peptide vaccine.
In his research on the topic of Adoptive cell transfer, Tumor antigen is strongly related with Tumor-infiltrating lymphocytes. His Antigen study combines topics in areas such as Tumor microenvironment, Cancer immunotherapy and T-cell receptor. His Immunotherapy research incorporates themes from Interleukin 2 and Lymphocyte.
His primary scientific interests are in Immunology, Melanoma, Antigen, Immunotherapy and Cancer research. He works mostly in the field of Immunology, limiting it down to concerns involving Cytotoxic T cell and, occasionally, Molecular biology and Cytokine. The study incorporates disciplines such as Cancer, Internal medicine, Oncology, Pathology and Peripheral blood mononuclear cell in addition to Melanoma.
The various areas that John R. Wunderlich examines in his Antigen study include Tumor antigen and T-cell receptor. His Immunotherapy study which covers Cell therapy that intersects with Clinical trial. His Cancer research research is multidisciplinary, relying on both Mutation, Cell growth and Somatic cell.
John R. Wunderlich mainly investigates Immunology, Cancer research, Melanoma, Cancer and Adoptive cell transfer. His Immunology research includes themes of Receptor and Chemotherapy. His work carried out in the field of Chemotherapy brings together such families of science as Cytotoxic T cell and Tumor-infiltrating lymphocytes.
His biological study deals with issues like Pathology, which deal with fields such as Cancer treatment. The concepts of his Cancer study are interwoven with issues in Lesion and Disease. John R. Wunderlich interconnects CD137 and Human papillomavirus in the investigation of issues within Adoptive cell transfer.
John R. Wunderlich focuses on Immunology, Immunotherapy, Melanoma, Antigen and Adoptive cell transfer. In his work, John R. Wunderlich performs multidisciplinary research in Melanoma and Response Evaluation Criteria in Solid Tumors. His Antigen study combines topics from a wide range of disciplines, such as Receptor, Somatic cell and Cancer immunotherapy.
His Adoptive cell transfer research includes elements of Cancer and Cancer research. His research in Cancer research intersects with topics in Sarcoma and NY-ESO-1. His studies in Internal medicine integrate themes in fields like Cytotoxic T cell and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes.
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang.
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu.
Nature Medicine (1998)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy
Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula.
Clinical Cancer Research (2011)
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry.
Journal of Clinical Oncology (2005)
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Eric Tran;Simon Turcotte;Alena Gros;Paul F. Robbins.
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang.
Journal of Clinical Oncology (2011)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
Mojgan Ahmadzadeh;Laura A. Johnson;Bianca Heemskerk;John R. Wunderlich.
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley;James C. Yang;Richard Sherry;Marybeth S. Hughes.
Journal of Clinical Oncology (2008)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Laura A. Johnson;Richard A. Morgan;Mark E. Dudley;Lydie Cassard.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: